Effects of golden hour thrombolysis: A Prehospital Acute Neurological Treatment and Optimization of Medical Care in Stroke (PHANTOM-S) substudy

JAMA Neurology

Volumn 72, Issue 1, 2015, Pages 25-30

  Ebinger, Martin ^a   Kunz, Alexander ^a   Wendt, Matthias ^a   Rozanski, Michal ^a   Winter, Benjamin ^a   Waldschmidt, Carolin ^a   Weber, Joachim ^a   Villringer, Kersten ^a   Fiebach, Jochen B ^a   Audebert, Heinrich J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR;

ADULT; AGED; AMBULANCE; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; COMORBIDITY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; EMERGENCY CARE; FEMALE; GERMANY; GOLDEN HOUR THROMBOLYSIS; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HOSPITAL INFORMATION SYSTEM; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PROSPECTIVE STUDY; STROKE EMERGENCY MOBILE UNIT; STROKE UNIT; TELEMEDICINE; TIME TO TREATMENT; EMERGENCY HEALTH SERVICE; FIBRINOLYTIC THERAPY; MIDDLE AGED; PROCEDURES; STROKE; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMBULANCES; EMERGENCY MEDICAL SERVICES; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS; PROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84921064683     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.3188     Document Type: Article

References (21)

1. Lees KR, Bluhmki E, von Kummer R, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695-1703.
2. Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309(23):2480-2488.
3. Fassbender K, Balucani C, Walter S, Levine SR, Haass A, Grotta J. Streamlining of prehospital stroke management: the golden hour. Lancet Neurol. 2013;12(6):585-596.
4. Audebert HJ, Saver JL, Starkman S, Lees KR, Endres M. Prehospital stroke care: new prospects for treatment and clinical research. Neurology. 2013;81(5):501-508.
5. Fonarow GC, Smith EE, Saver JL, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123(7):750-758.
6. Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA. 2014;311(16):1632-1640.
7. Wahlgren N, Ahmed N, Dávalos A, et al; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275-282.
8. Lorenzano S, Ahmed N, Tatlisumak T, et al; SITS Investigators. Within-day and weekly variations of thrombolysis in acute ischemic stroke: results from Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register. Stroke. 2014;45(1):176-184.
9. Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology. 2012;79(4):306-313.
10. Köhrmann M, Schellinger PD, Breuer L, et al. Avoiding in hospital delays and eliminating the three-hour effect in thrombolysis for stroke. Int J Stroke. 2011;6(6):493-497.
11. Walter S, Kostopoulos P, Haass A, et al. Point-of-care laboratory halves door-to-therapy-decision time in acute stroke. Ann Neurol. 2011;69(3):581-586.
12. Meretoja A, Weir L, Ugalde M, et al. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology. 2013;81(12):1071-1076.
13. Walter S, Kostopoulos P, Haass A, et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol. 2012;11(5):397-404.
14. Weber JE, Ebinger M, Rozanski M, et al; STEMO-Consortium. Prehospital thrombolysis in acute stroke: results of the PHANTOM-S pilot study. Neurology. 2013;80(2):163-168.
15. Ebinger M, Winter B, Wendt M, et al; STEMO Consortium. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. JAMA. 2014;311(16):1622-1631.
16. Ebinger M, Rozanski M, Waldschmidt C, et al; STEMO-Consortium. PHANTOM-S: the Prehospital Acute Neurological Therapy and Optimization of Medical Care in Stroke Patients study. Int J Stroke. 2012;7(4):348-353.
17. Ebinger M, Lindenlaub S, Kunz A, et al. Prehospital thrombolysis: a manual from Berlin. J Vis Exp. 2013;(81):e50534. doi:10.3791/50534.
18. Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20(7): 864-870.
19. Sandercock P, Wardlaw JM, Lindley RI, et al; IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial [published correction appears in Lancet. 2012;380(9843):730]. Lancet. 2012;379(9834): 2352-2363.
20. Meretoja A, Keshtkaran M, Saver JL, et al. Stroke thrombolysis: save a minute, save a day. Stroke. 2014;45(4):1053-1058.
21. Grotta JC. tPA for stroke: important progress in achieving faster treatment. JAMA. 2014;311(16): 1615-1617.